The FDA received and reviewed the Pfizer manuscript for a class IIb non-Hodgkins Lymphoma vaccine. It was found that the combination of astragulus and a caspase, a type of protein used in making many kinds of blood clotting factors, caused a condition known as panleukopenia. It is a type of autoimmune disease characterized by an immune deficiency leading to inflammation and bleeding of the lymph nodes. This is not the same as leukemia. The treatment caused a rare condition called cyclosporiasis that can cause infection of the intestinal lining.
Pfizer’s vaccine is one of many that contain an immune system response called intracellular antibody-receptor activity (IRA) and is related to antibodies. These are proteins, usually proteins produced by cells, that trigger a defense response by causing white blood cells to attack foreign antigens. The immune response is generally protective; the body responds by making antibodies against the allergen. The problem is that the antibodies do not discriminate between good and bad allergens, or what aggravates allergies. This leads to allergen exposure leading to allergy symptoms.
Other vaccine safety concerns include the protein structures themselves. A recent study showed that the aluminum contained in thimerosal can bind with the protein glycine, causing a toxic compound known as polysulfate to be formed. There has been concern about the negative affects of this on neurological development in children. The FDA has determined that there is no evidence that the aluminum content of the Pfizer Product Interaction Site of Intragener Medium (PIM) increases the risk of neurological disorders. However, the agency is concerned about the potential for an effect of the aluminum on the blood pressure of infants and children.
The combination of ingredients used in some vaccines have also raised questions. One concern is how the combination affects the body’s immune system. The human immune system requires various types of nutrients to perform at peak levels. Drugs that enhance an individual’s immunity cannot be expected to stand alone. Most experts agree that the best approach is to combine the drugs in a clinically proven fashion that allows the body to naturally assimilate them.
Pfizer has released a statement saying that they plan to “actively evaluate” any studies that are done by outside sources with this issue. They have received reports from outside sources that raised questions about their vaccine. These reports were all submitted prior to the licensing of the Pfizer vaccine. While the company will not say whether or not the studies are legitimate, they have stated that they are conducting “a thorough review of all data prior to scheduling the vaccine.” It is unknown when they will make a determination on their findings. Until then, the consumer will continue to be cautious about these vaccines.
Some other vaccine ingredients have shown to be problematic as well. Liveatten, one of the major producers of human immunodeficiency virus (HIV) antigens, found problems with their rheumatic fever vaccine Vaxamine in Europe. An official investigation into the Vaxamine case found that the ingredient Mycelex was improperly combined with other substances.
One major concern with Vaxamine was the use of mRN transcripts in the vaccine. This is the same material that could cause issues with those who are allergic to eggshells. This mRN protein matches the foreign protein that the body’s natural immunity reacts to. Those who are highly sensitive to this protein should avoid this vaccine while ages twelve and older. For healthy adults, the mRN vaccine is considered relatively safe. Pfizer has stated recently that they have found no safety concerns with the Pfizer mRNA vaccine, although testing and human trials have only recently been initiated. Long term results of use may require years to fully understand.
mRNA Vaccines; part of modern medical vaccination history
An mRNA vaccine or mRNA protein vaccine is a kind of vaccine that makes use of an artificially made copy of an active protein gene or messenger RNA to produce a protective response in a cell. Usually, the vaccine induces expression of the genes it contains within the target cells. The messenger ribonucleic acid, or mRNA, is transcribed by ribosomes into mRNA transcripts that are later translated into messenger ribonucleic acid and then into protein. Since the mRNA is transcribed directly to DNA, it contains a long stretch of mRNA transcripts that serves as the genetic material or template for making any type of cellular protein. The mRNA contains multiple copies of the genetic material which enables the cell to regulate protein synthesis and development.
The major advantage of mRNA vaccines over dna vaccines is that they can stimulate a higher level of transcriptional activity than dna-based vaccines do. This means that the amount of mRNA available to transcriptional programs is higher. These mrna proteins are generated from genetically engineered viruses that have been specifically designed to elicit expression of specific mRNAs. This technology has made it possible to generate high quality mRNAs from genetically engineered viruses.
Scientists are testing two men vaccines currently. One of these is developed by GenF20 using an EcoTox hybridoma virus and another is developed by scientists at the University of Edinburgh in the UK, named LiuLuv. The LiuLuv vaccine uses a genetically engineered strain of the Eco Tetra Virus. This particular strain belongs to the EcoTox family.
The many vaccines are undergoing the third phase of the development process. During the third phase, the vaccines go through several safety screening procedures and further tests are performed to ensure the product is suitable for human consumption and other potential exposures. During the second phase, vaccine candidates are evaluated using various parameters. These parameters are specific to each vaccine. For example, in the vaccine trial conducted by GenF20, the subjects experienced no major illness or symptoms.
The third phase of mRNA vaccine development involves experimental infections with the mrsna vaccine candidates under controlled conditions. The purpose of this phase is to determine whether the viral proteins produced by the mrsna vaccine are capable of stimulating an adequate immune response in humans. To this end, it is common for vaccine development companies to perform polymerase chain reaction (PCR) experiments using various viruses. These experiments use various forms of animal models to assess the ability of the mrsna vaccines to stimulate an adequate immune response in humans.
The use of animal models in biotechnology research and drug development is vital because it helps to reduce the risks associated with potential toxicities of the products. For example, the use of mice as a model for vaccine trials is preferred by some pharmaceutical companies due to their high tolerance to chemical toxins. Additionally, animal studies have provided important information on the long-term toxicities of various biological agents that have been developed as vaccines. Based on these findings, the drug makers choose not to use mice in their arena vaccines.
The last phase of mRNA vaccines involves usage of animal resources in the production of human dosage forms of the mrsna vaccines. This commonly requires the use of animal sources that are rich in natural transcript transcripts of the genes that code for the viral proteins. For example, the mrsna vaccines that contain V3 vertebrate transcript are prepared from VGA animal sources that code for delta fosferal full receptor, which is a key factor involved in the paralysis and spasticity of the patient suffering from tetanus. Animal resources used in this production include chicken eggs, liver, kidney and bovine heart tissues. The production of these animal sources also makes use of animal resources that are suitable for viral RNA transcription. The mrsna proteins need to undergo stringent purification steps to ensure that they do not generate any heat damage during processing.
The manufacturing of mRNA vaccines is an extremely complex process, involving multiple steps along the way. However, the progress made in this field has paved the way for production of highly efficient arena vaccines. With the increasing safety of the public and medical communities, mRNA vaccines are fast replacing traditional live vaccines in both domestic and clinical Trials around the globe.